Wednesday, July 22, 2026 A huge milestone for CCTG MA.39 Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer has successfully reached the sample size of 2,140 participants and is now closed to further accrual.The study is accessing the need for regional radiotherapy after breast surgery and the ability of biomarkers to predict the risk of local recurrence and the effectiveness of radiation. The results will determine if regional radiotherapy can be safely omitted in women with 1-3 positive axillary lymph nodes and luminal A subtype. Although regional radiation therapy is part of standard treatment, recent research suggests that receiving no regional radiation may work just as well in some low-risk types of breast cancer. The benefits o which includes participants from across Canada and the US.f not receiving regional radiation therapy may include fewer clinic visits and side effects, better quality of life, and less cost over time for the healthcare system. Dr. Tim Whelan from Juravinski Cancer Centre at London Health Sciences is the Study Chair."The MA.39 trial exemplifies the ability of the NCTN to undertake rigorously designed and conducted patient centred trials which address patient values and cancer outcomes," says Dr. Wendy Parulekar, the study Senior Investigator. "Data collection continues on all participants, and we are grateful to our collaborators for their ongoing support of this important trial."
